<DOC>
	<DOCNO>NCT02057523</DOCNO>
	<brief_summary>The goal study evaluate benefit ACTH ( Acthar ) reduce proteinuria associate transplant glomerulopathy non-diabetic kidney transplant recipient .</brief_summary>
	<brief_title>Acthar Rescue Therapy Transplant Glomerulopathy Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<mesh_term>Melanocyte-Stimulating Hormones</mesh_term>
	<mesh_term>beta-Endorphin</mesh_term>
	<criteria>Kidney transplant recipient confirm transplant glomerulopathy kidney biopsy . Failed standard therapy ( &gt; 25 % reduction proteinuria ) include maximum use ACE inhibitor , ARB , aldosterone blocker goal blood pressure le 130/80 optimization immunosuppression Diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>